Apex Therapeutics CEO, David Broecker, presented at the 2015 BIO International Convention in Philadelphia. June 16. He provided an update on the achievement of corporate milestones and outline the plans for the development of APX3330 for the treatment of pancreatic cancer.
The company recently achieved several company milestones including:
- Issued patent US#9,040,505 on a method for inhibiting pancreatic cancer through the administration of APX3330. This patent provides for exclusivity in the United States for APX3330 through September 21, 2030.
- Positive feedback from the FDA on the IND-acceptability of preclinical, toxicology, and clinical data from a previous development program that examined a well-tolerated dose administration of APX3330 (E3330) in non-cancer indications by Eisai Pharmaceuticals (Tokyo, Japan).
- Plans to initiate a phase I/IIA study in early 2016 for the development of APX3330 in the treatment of pancreatic cancer. The phase I/IIA study will determine the maximum-tolerated-dose in a cohort of refractory, solid tumor cancer patients to be followed in a cohort of pancreatic-only cancer patients.